Desmopressin In The Treatment of Postural Orthostatic Tachycardia
|
|
- Zoe Waters
- 6 years ago
- Views:
Transcription
1 The Journal of Innovations in Cardiac Rhythm Management, 6 (2015), DOI: /icrm PHARMACOLOGICAL THERAPY RESEARCH ARTICLE Desmopressin In The Treatment of Postural Orthostatic Tachycardia DAVID GACHOKA, MD 1, KHALIL KANJWAL, MD, FACC, FHRS, CCDS 2 (JOINT FIRST AUTHORS), BEVERLY KARABIN, PhD 1 and BLAIR P. GRUBB, MD, FACC 1 1 Division of Cardiology, Department of Medicine, The University of Toledo Medical Center, OH 2 Michigan Cardiovascular Institute, Central Michigan University, Saginaw, MI ABSTRACT. The long-term efficacy of desmopressin (DDAVP) in treatment of postural orthostatic tachycardia syndrome (POTS) patients remains unclear. We report our retrospective, single-center, long-term experience regarding the efficacy and adverse effect profile of DDAVP in the treatment of POTS patients. In this retrospective analysis, we reviewed the electronic charts for data in regards to patient demographics, orthostatic parameters, side effect profile, subjective response to therapy, and laboratory studies recorded for each clinical follow-up visit at our institution s Syncope and Autonomic Disorder Center. The response to DDAVP therapy was considered successful if the patient had both symptom relief in addition to an objective response in orthostatic hemodynamic parameters including (heart rate (HR) and systolic blood pressure (SBP)). Three hundred and fifty POTS patients were screened for evaluation in this study. Of the 350 patients, 72 patients who received DDAVP therapy were reviewed. Forty-eight patients from this group wereabletotolerate themedication aftercareful dosage titration. Mean follow-up duration in this group of patients was 12±2 months(10 14) months. DDAVP improved symptoms of orthostatic intolerance in 20 of 72 (28%) ofthetotalpatients or20of 48 (42%) ofthosewhowereableto toleratethe drug.symptoms thatimprovedthe mostincluded dizziness (48%), presyncope (38%), fatigue 18%, palpitations(33%), anxiety (42%), and syncope (20%). Symptom reduction correlated with a statistically significant improvement in standing HR after treatment with DDAVP compared with their baseline hemodynamic parameters (standing HR ±12.67 versus 92.10±18.62, po0.03). The most common side effect was hyponatremia n ¼ 9, 20%). In the subgroup of patient with POTS who can tolerate oral DDAVP, there was notable improvement of standing HR, which correlated with improvement inclinicalsymptoms oforthostatic intolerance. ISSN (print) ISSN (online) KEYWORDS. desmopressin, postural orthostatic tachycardia syndrome Innovations in Cardiac Rhythm Management Introduction Postural orthostatic tachycardia syndrome (POTS) is a form of chronic orthostatic intolerance associated with an The authors report no conflicts of interest for the published content. Manuscript received September 14, 2015, final version accepted November 30, Address correspondence to: Blair P. Grubb, MD, FACC, Professor of Medicine, The University of Toledo Medical Center, 3000 Arlington Ave, Toledo, OH Blair.Grubb@utoledo.edu *ThispaperisdedicatedtoBarbaraStraus,MD( ).Physician, mother, community leader, dancer, and loving wife (B.P.G.). May her memory be for a blessing. excessive rise in heart rate (HR) during an upright posture that resolves with recumbency. A constellation of symptoms is experienced by patients suffering from POTS, which may include palpitation, dizziness, and fatigue. These symptoms may result in limitation of their daily activities to an extent of functional disability that leads to loss of both educational and employment opportunities. Currently, there is no FDAapproved therapy for patients suffering from this problem. Desmopressin (DDAVP) is a synthetic analogue of arginine vasopressin that has been in use for a long time in the prevention of enuresis in children. It acts by promoting fluid retention by increasing water permeability in the distal tubule of the kidney. Through this mechanism, it promotes 2222 The Journal of Innovations in Cardiac Rhythm Management, December 2015
2 D. Gachoka, K. Kanjwal, B. Karabin, et al. acute blood volume expansion and may reduce orthostatic tachycardia in POTS patients. There is anecdotal evidence on the use of DDAVP as an add-on therapy in management of POTS. We herein present our experience with the use of DDAVP in patients with POTS who were followed at our autonomic center. Methods This was a retrospective study approved by our institutional review board at the University of Toledo medical center. We reviewed 350 electronic medical records (EMRs) of patients with POTS who had been treated at our autonomic center. A total of 72 patients were found to be eligible for inclusion in this study. Criteria for diagnosis of POTS POTS was defined as ongoing symptoms of orthostatic intolerance lasting more than 6 months accompanied by a HR increase of at least 30 bpm or a HR of more than 120 bpm observed during the first 10 min of upright posture or the head-up tilt test (HUTT) occurring in the absence of another chronic debilitating disorder. 1 6 Reported symptoms included fatigue, orthostatic palpitation, exercise intolerance, dizziness or lightheadedness, headache, near syncope, and/or syncope. In a retrospective detailed chart review, we collected data to include presenting symptoms, demographic information, laboratory data, and treatment outcome with DDAVP. Protocol for HUTT The protocol for tilt-table testing has been described extensively elsewhere in our previous work on POTS. 1,5 Treatment protocol Patients treatment protocols were based on our previous experiences with orthostatic disorders as described in detail elsewhere. 3,4 Sequence of therapies employed in this condition included physical counter maneuvers, aerobic and resistance training, as well as increased dietary fluids and sodium. If these therapies were ineffective, pharmacotherapy was initiated in a sequence generally consisting ofb-blockers, central sympatholytic, fludrocortisone, midodrine, and Total patients screened n=350 Elligible patients n= 72 Number that discontinued ddavp due to SE n=14 Lost to follow up n=10 number that complained of hyponatremia n= 9 patients who continued DDAVP through dose titration n=48 Clinical response to DDAVP on 0.1 mg n=5 clinical response to DDAVP on 0.2mg n= 15 patient non responsive to DDAVP n=28 Figure 1: Diagram summarizing the design and response to desmopressin in patients suffering from refractory postural orthostatic tachycardia syndrome. The Journal of Innovations in Cardiac Rhythm Management, December
3 Desmopressin in the Treatment of Postural Orthostatic Tachycardia selective serotonin reuptake inhibitors either alone or in combination. If patients failed to respond to these medications,secondand third-line therapies such as octreotide, erythropoietin, and pyridostigmine were employed. Being a referral center for POTS patients, our study had a higher number of drug refractory patients. As such, these POTS patients were on multiple medications upon presentation, and DDAVP was added on slowly while escalating dosage to assess response and efficacy in patients who failed to respond to the minimum dose. The process was aimed at assessing the usefulness of DDAVP as an adjunct to existing therapy. DDAVP was therefore a third-line add-on therapy in patients who were still symptomatic despite the use of the above agents. We did not employ a formal questionnaire or a composite autonomic severity score (CASS) to assess the response to treatment. The information about the subjective symptoms, overall symptom improvement with treatment, and side effects was collected from the patient s EMR and communication from the physician. Treatment was considered successful if the patient reported symptomatic relief and if the hemodynamic parameters showed improvement compared with previous readings. At each visit, HR and blood pressure (BP) readings were collected in both the supine position and after 10 min of standing. We used descriptive statistics to report our findings. DDAVP was not given to women on oral contraceptives because of the potential for thrombotic complications Follow-up The median length of follow-up was 12±2 months (range months). The study data were collected from patient population seen in our outpatient clinic between 2005 and DDAVP use All patients were initially started on 0.1 mg DDAVP orally once daily. If no significant therapeutic effect was reported and they could still tolerate the medication, the dose was increased to a maximum of 0.2 mg orally once daily. Results A total of 350 patients had visited our clinic with diagnosis of POTS. Of those, 72 were eligible for inclusion in this study (Figure 1). Table 1 shows the population baseline characteristics. Seventy-two patients were eligible, of whom 56 (78%) were women. Ten patients (13%) were lost to follow-up while 14 patients (19%) reported side effects to DDAVP leading them to stop taking the medication. The most common reported side effect was hyponatremia in 12% of the patients, with the lowest sodium level being 125 meq/l. In each of these patients serum sodium levels returned to pretreatment levels within 3 4 weeks after stopping the medication. A total of 48 patients (67%) were able to tolerate DDAVP or go through titration to the maximum dose. DDAVP was initiated at a dose of 0.1 mg daily. If the patient tolerated Table 1: Demographic and clinical feature of the study patients Baseline clinical characteristics of patients in the study Study characteristics Total number of patients screened 350 Number of patients who met inclusion criteria 72 Number of patients that received Desmopressin 72 Number of patient with incomplete follow up 10 Number of patients with side effects 14 Clinical features in patients included in the 48 analysis Age (yrs) 39±18 Females 38 Comorbidities, n (%) Migraine 22 (45.0%) Diabetes 2 (4.0%) Joint hypermobility 1 (2.0%) Hypertension 6 (12.5%) Wolf Parkinson White syndrome 2 (4.0%) Cerebral palsy 1 (2.0%) Delta granules disease 5 (10.4%) Factor 5 Leiden deficiency 2 (4.0%) Precipitating event Viral infection 8 (16.6%) Surgery 5 (10.4%) Trauma 2 (2.0%) pregnancy 3 (6.2%) Clinical symptoms of POTS, n (%) Fatigue 21 (44.0%) Dizziness 31 (65.0%) presyncope 38 (79.0%) Syncope 5 (10.4%) Inability to concentrate 6 (12.5%) Orthostatic palpitation 21 (44.0%) Chest pain 4 (8.3%) Anxiety 7 (14.5%) hypersomnolence 4 (8.3%) Nausea 6 (12.5%) Concomitant medications (n%) b-blocker 16 (33.3%) Midodrine 23 (47.9%) Modafinil 8 (16.6%) Fludrocortisone 25 (52.1%) Octreotide 3 (6.2%) Erythropoietin 5 (10.4%) Norepinephrine reuptake inhibitors 2 (4.0%) Selective serotonin reuptake inhibitor 16 (33.3%) Methylphenidate 2 (4.0%) POTS: postural orthostatic tachycardia syndrome. the medication, symptom improvement was re-evaluated after 6 months. If no subjective change in the symptoms was reported, the dose was increased to 0.2 mg orally once daily. After another 6 months, symptoms and hemodynamic parameters were re-evaluated on the higher dose. Effects of DDAVP on hemodynamic parameters Table 2 provides the effects of DDAVP on hemodynamic parameters between the first and second visit, including improved HR from sitting to standing position without significant effect on the systolic blood pressure (SBP) The Journal of Innovations in Cardiac Rhythm Management, December 2015
4 D. Gachoka, K. Kanjwal, B. Karabin, et al. Table 2: Hemodynamic effects of desmopressin Before treatment After treatment p-value Sitting heart rate 84.04± ±21.53 NS Standing heart rate ± ± Sitting systolic blood pressure ± ±22.89 NS Standing systolic blood pressure ± ±16.90 NS Some of the commonly reported side effects of DDAVP use were hyponatremia, swelling of the arms and digits, headache, and mild confusion. Hyponatremia was the most common reason for discontinuing DDAVP. No patient ith headaches was reported to have signs of increased intracranial pressure such as papilledema. Discussion POTS often affects individuals between 15 and 50 years of age. The ratio of female to male patients is 5:1. 1 Treatment of POTS patients is often very challenging, with nonpharmacological therapy focused on increasing salt and fluid intake, compression stockings, and exercise. 1,7,8 The goal of the therapy is to reduce both the frequency and the severity of their symptoms and improve their quality of life. 9 DDAVP is a synthetic analog of vasopressin, a natural antidiuretic hormone that acts through the principle cells of the collecting duct to reabsorb water into the bloodstream, resulting into increased total effective body volume 2,6 (Figure 2). DDAVP has been used in children to treat enuresis with few side effects noted. In a prospective randomized control study looking at acute effects of DDAVP, a significant reduction in the standing HR was observed when compared with placebo (HR 101.9±14.5 bpm compared with 109.2±17.4 bpm; po0.001). This acute effect on the HR was associated with acute symptomatic improvement; 2 however, the magnitude of HR reduction did not correlate with the degree of symptom resolution. In our analysis, DDAVP use was associatedwithimprovement in the clinical symptoms of POTS. The most notable symptoms that improved included dizziness, fatigue, palpitation, nausea and syncope (Table 3). This improvement was most likely related to the improved hemodynamic changes (particularly HR) observed following DDAVP administration similar to the previous study. There was no significant change in SBP noted to correlate with POTS symptoms improvement. Figure 2: Site of action of desmopressin on the colleting tubules of the nephron (illustration by Helen Grubb). The Journal of Innovations in Cardiac Rhythm Management, December
5 Desmopressin in the Treatment of Postural Orthostatic Tachycardia Table 3: Most common reported improved symptoms Symptoms Number with symptoms before treatment Number with symptoms after treatment Improvement (%) Presyncope Dizziness Fatigue Palpitation Anxiety Syncope The overall efficacy of DDAVP in our study was 28% of the total patients and 42% of the patients who were able to tolerate the drug. We did not find any specific clinical features that predicted a response to DDAVP therapy. Most of the patients who reported no improvement with (or were intolerant of) DDAVP use were also noted to be resistant to or intolerant of other therapeutic regimens as well. Hyponatremia was noted to be the most common adverse effect and the most common reason for discontinuation of this medication; however, the lowest sodium level seen was 125 meq/l and sodium levels returned to normal within weeks of stopping the medication. This side effect was perhaps compounded by the fact that a large volume of fluid intake is one non-pharmacological way to manage POTS symptoms. Other reported side effects though at lesser frequency included headache, nausea, and swelling of digits, which are all related to water retention. We noted a mild drug drug interaction between DDAVP and fludrocortisone leading to enhanced water retention and swelling of the digits. Special attention should be paid to this adverse effect when using these medications concomitantly. Nonetheless, DDAVP appears to be a potentially safe, effective, and inexpensive treatment modality in the treatment of POTS. In light of the expense of other treatment modalities (such as octreotide, erythropoietin, and ivabradine), it seems reasonable to consider DDAVP earlier in the treatment of patients suffering from POTS. Limitations Several limitations were noted during this study. Because of its retrospective nature, randomization of the study population was not possible and each patient served as their own control. The study also lacked standardized criteria for evaluating the efficacy of therapy or assessing the hemodynamic response during treatment. The beneficial effect of DDAVP noted in our study may therefore have been a spontaneous remission of this condition. However, considering that these patients had previously been refractory to other treatment regimens, we can argue their symptomatic improvement was secondary to DDAVP addition. As a referral center, the patients presenting to our clinic were highly symptomatic and had not responded to trials of multiple medication. Conclusion A subgroup of POTS patients who can tolerate DDAVP through dose titration may demonstrate improvement in both standing HR and their clinical symptoms. Overall the agent is safe, inexpensive, and easy to use and should be considered as an additional therapeutic modality in the treatment of POTS. References 1. Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2009; 20(3): Coffin ST, Black BK, Biaggioni I, et al. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm. 2012;9(9): Grubb B, Dan GA. Syncope due to autonomic insufficiency syndromes associated with orthostatic intolerance. Rom J Intern Med ;38 39: Grubb BP, Kanjwal Y, Kosinski DJ. The postural tachycardia syndrome: A concise guide to diagnosis and management. JCardiovascElectrophysiol.2006;17(1): Grubb BP, Kosinski D. Tilt table testing: Concepts and limitations. Pacing Clin Electrophysiol. 1997;20(3 Pt 2): Weinstock J. Desmopressin in the postural tachycardia syndrome. Heart Rhythm. 2012;9(9): Grubb BP. Postural tachycardia syndrome. Circulation. 2008; 117(21): Kavi L, Gammage MD, Grubb BP, Karabin BL. Postural tachycardia syndrome: Multiple symptoms, but easily missed. Br J Gen Pract. 2012;62(599): Grubb BP. Clinical practice. Neurocardiogenic syncope. N Engl J Med. 2005;352(10): The Journal of Innovations in Cardiac Rhythm Management, December 2015
Pyridostigmine in the Treatment of Postural Orthostatic Tachycardia: A Single-Center Experience
Pyridostigmine in the Treatment of Postural Orthostatic Tachycardia: A Single-Center Experience KHALIL KANJWAL, M.D.,* BEVERLY KARABIN, PH.D.,* MUJEEB SHEIKH, M.D.,* LAWRENCE ELMER, M.D., PH.D., YOUSUF
More informationUse of Methylphenidate in the Treatment of Patients Suffering From Refractory Postural Tachycardia Syndrome
American Journal of Therapeutics 0, 000 000 (2010) Use of Methylphenidate in the Treatment of Patients Suffering From Refractory Postural Tachycardia Syndrome Khalil Kanjwal, MD, 1 Bilal Saeed, MD, 2 Beverly
More informationPOSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) IT S NOT THAT SIMPLE
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) IT S NOT THAT SIMPLE POTS Irritable heart syndrome. Soldier s heart. Effort syndrome. Vasoregulatory asthenia. Neurocirculatory asthenia. Anxiety neurosis.
More informationFindings from the 2015 HRS Expert Consensus Document on Postural Tachycardia Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST)
Findings from the 2015 HRS Expert Consensus Document on Postural Tachycardia Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST) Ahmad Hersi, MBBS, MSc, FRCPC Professor of Cardiac Sciences Consultant
More informationSyncope Guidelines: What s New?
Syncope Guidelines: What s New? Dr. Samuel Asirvatham Professor of Medicine and Pediatrics Mayo Clinic College of Medicine Medical Director, Electrophysiology Laboratory Program Director, EP Fellowship
More informationPostural Orthostatic Tachycardia Syndrome:
Postural Orthostatic Tachycardia Syndrome: A Case Presentation Interesting Cases from the Annals of Women s Heart Care I have no financial relationships or commercial interests to disclose that are relevant
More informationContempo GIMSI Cosa cambia alla luce della letteratura in tema di terapia farmacologica
Contempo GIMSI 2015-2017 Cosa cambia alla luce della letteratura in tema di terapia farmacologica Dott.ssa Diana Solari Centro Aritmologico e Sincope Unit, Lavagna www.gimsi.it POST 2 (Prevention of Syncope
More information:{ic0fp'16. Geriatric Medicine: Blood Pressure Monitoring in the Elderly. Terrie Ginsberg, DO, FACOI
:{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Geriatric Medicine: Blood Pressure Monitoring in the Elderly Terrie Ginsberg, DO, FACOI Blood Pressure Management in the Elderly Terrie B.
More informationCase Report Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump
Case Reports in Medicine Volume 2015, Article ID 545029, 4 pages http://dx.doi.org/10.1155/2015/545029 Case Report Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered
More informationExercise Training for PoTS and Syncope
B 140 120 100 80 60 40 20 0 Blood Pressure (mm Hg) Blood Pressure Heart Rate 60 degree Head Up Tilt Time 140 120 100 80 60 40 20 0 Heart Rate (beats.min -1 ) Exercise Training for PoTS and Syncope C Blood
More informationINTRODUCTION POTS is: Poorly understood Rarely considered SIGNIFICANT morbidity Appropriate initial diagnosis & care will expedite management of POTS
Learning objectives At the end of this presentation the learner should: Define POTS & identify the various etiologies of POTS Be able to differentiate POTS from other causes of orthostatic intolerance
More informationThe Postural Tachycardia Syndrome: A Concise Guide to Diagnosis and Management
108 TECHNIQUES AND TECHNOLOGY Editor: Hugh Calkins, M.D. The Postural Tachycardia Syndrome: A Concise Guide to Diagnosis and Management BLAIR P. GRUBB, M.D., YOUSUF KANJWAL, M.D., and DANIEL J. KOSINSKI,
More informationI Can t Think Properly Brian Fog & POTS
I Can t Think Properly Brian Fog & POTS Satish R Raj MD MSCI FACC FHRS Libin Cardiovascular Institute of Alberta University of Calgary Autonomic Dysfunction Center Vanderbilt University School of Medicine
More informationNorthera (droxidopa)
Northera (droxidopa) Policy Number: 5.01.657 Last Review: 07/2018 Origination: 07/2018 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Northera
More informationPostural Tachycardia Syndrome and Hypermobility Syndrome
Postural Tachycardia Syndrome and Hypermobility Syndrome Blair P. Grubb MD FACC Departments of Medicine and Pediatrics Health Science Campus University of Toledo Toledo, Ohio USA Over the years it became
More informationPostural Orthostatic Tachycardia Syndrome (POTS): Evaluation and Management
BJMP 2012;5(4):a540 Review Article Postural Orthostatic Tachycardia Syndrome (POTS): Evaluation and Management Ronald Conner, Mujeeb Sheikh and Blair Grubb Abbreviations JHS - Joint hypermobility syndrome,
More informationNORTHERA (droxidopa) oral capsule
NORTHERA (droxidopa) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationRehabilitation for Postural Tachycardia Syndrome (POTS)
Rehabilitation for Postural Tachycardia Syndrome (POTS) Satish R Raj MD MSCI FACC FHRS FRCPC Associate Professor of Cardiac Sciences University of Calgary Adjunct Associate Professor of Medicine Autonomic
More informationIvabradine in Inappropriate Sinus Tachycardia
UNIVERSITA DEGLI STUDI DI MILANO I.R.C.C.S POLICLINICO SAN DONATO CENTRO PER LO STUDIO E LA TERAPIA DELLLE MALATTIE CARDIOVASCOLARI E. MALAN Ivabradine in Inappropriate Sinus Tachycardia Riccardo Cappato,
More informationTilt training EM R1 송진우
Tilt training 2006.7.15. EM R1 송진우 Introduction North American Vasovagal Pacemaker Study Randomized, controlled trial Reduction in the likelihood of syncope by dual chamber pacing with rate drop response
More informationDisclosures. Adult Postural Orthostatic Tachycardia Syndrome (POTS) Topics. Objectives. Definition/Terminology. Epidemiology 2/2/2017
Disclosures Adult Postural Orthostatic Tachycardia Syndrome (POTS) Nothing to disclose (no financial or pharmaceutical affiliations) All discussed pharmacologic treatments are off-label Juan J. Figueroa,
More informationSyncope Update Dr Matthew Lovell, Consultant in Cardiology
Syncope Update Dr Matthew Lovell, Consultant in Cardiology Definition of Syncope Syncope is defined as TLOC due to cerebral hypoperfusion Characterized by a rapid onset, short duration, and spontaneous
More informationTreatment of Postural Orthostatic Tachycardia Syndrome and Inappropriate Sinus Tachycardia
Treatment of Postural Orthostatic Tachycardia Syndrome and Inappropriate Sinus Tachycardia M. Yousuf Kanjwal, MD*, Daniel J. Kosinski, MD, and Blair P. Grubb, MD Address *Medical College of Ohio, Room
More informationSYNCOPE. Sanjay P. Singh, MD Chairman & Professor, Department of Neurology. Syncope
SYNCOPE Sanjay P. Singh, MD Chairman & Professor, Department of Neurology. Syncope Syncope is a clinical syndrome characterized by transient loss of consciousness (TLOC) and postural tone that is most
More informationEvaluation of Dizziness and Fainting in Children and Adolescents
Evaluation of Dizziness and Fainting in Children and Adolescents Collin Cowley, MD - Pediatric Cardiology Lynne Kerr, MD, PhD Pediatric Neurology Chuck Norlin, MD General Pediatrics Bettina Smith Edmondson,
More informationPatient O.T. is a 26-year-old white
Clinician Update Postural Tachycardia Syndrome (POTS) Satish R. Raj, MD, MSCI Patient O.T. is a 26-year-old white woman who works in the music industry. She was diagnosed with pneumonia and treated with
More informationTreatment of orthostatic hypotension in Multiple System Atrophy New Clinical Studies
Treatment of orthostatic hypotension in Multiple System Atrophy New Clinical Studies Cyndya A. Shibao, M.D., F.A.H.A. Assistant Professor of Medicine Division of Clinical Pharmacology Disclosure Lundbeck
More informationNocdurna (desmopressin acetate) NEW PRODUCT SLIDESHOW
Nocdurna (desmopressin acetate) NEW PRODUCT SLIDESHOW Introduction Brand name: Nocdurna Generic name: Desmopressin acetate Pharmacological class: Vasopressin (synthetic) Strength and Formulation: 27.7mcg,
More informationSyncope: Evaluation of the Weak and Dizzy
Syncope: Evaluation of the Weak and Dizzy William M. Miles, MD, FACC, FHRS Professor of Medicine Silverstein Chair for Cardiovascular Education University of Florida College of Medicine Disclosures Medtronic,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Northera) Reference Number: CP.PMN.17 Effective Date: 08.01.16 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationW J C C. World Journal of Clinical Cases. Reversible postural orthostatic tachycardia syndrome. Abstract CASE REPORT. Aza Abdulla, Thirumagal Rajeevan
W J C C World Journal of Clinical Cases Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.12998/wjcc.v3.i7.655 World J Clin Cases 2015 July 16;
More informationAutonomic Dysfunction Presenting as Postural Orthostatic Tachycardia Syndrome in Patients with Multiple Sclerosis
62 Research Paper International Journal of Medical Sciences 2010; 7(2):62-67 Ivyspring International Publisher. All rights reserved Autonomic Dysfunction Presenting as Postural Orthostatic Tachycardia
More informationSyncope: Evaluation of the Weak and Dizzy
Syncope: Evaluation of the Weak and Dizzy William M. Miles, MD, FACC, FHRS Professor of Medicine Silverstein Chair for Cardiovascular Education University of Florida College of Medicine Disclosures Medtronic,
More informationTitrating Critical Care Medications
Titrating Critical Care Medications Chad Johnson, MSN (NED), RN, CNCC(C), CNS-cc Clinical Nurse Specialist: Critical Care and Neurosurgical Services E-mail: johnsoc@tbh.net Copyright 2017 1 Learning Objectives
More informationPostural tachycardia syndrome is associated with significant symptoms and functional impairment predominantly affecting young women: a UK perspective
Research Postural tachycardia syndrome is associated with significant symptoms and functional impairment predominantly affecting young women: a UK perspective Claire McDonald, 1 Sharon Koshi, 1 Lorna Busner,
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationTilt Table Testing MM /01/2015. HMO; PPO; QUEST Integration 09/22/2017 Section: Medicine Place(s) of Service: Office, Outpatient
Tilt Table Testing Policy Number: Original Effective Date: MM.02.024 01/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 09/22/2017 Section: Medicine Place(s) of Service:
More informationDiagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study
Diagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study Learning Objectives: Illustrate how to accurately diagnose noh Employ scales and questionnaires in combination with cardiovascular
More informationJune 8, 2018, London UK TREATMENT OF VASOVAGAL SYNCOPE
June 8, 2018, London UK TREATMENT OF VASOVAGAL SYNCOPE Where to go for help Syncope: HRS Definition Syncope is defined as: a transient loss of consciousness, associated with an inability to maintain postural
More informationClinical Studies 129
Clinical Studies 129 Syncope in migraine. The population-based CAMERA study Roland D. Thijs, 1* Mark C. Kruit, 2* Mark A. van Buchem, 2 Michel D. Ferrari, 1 Lenore J. Launer, 3,4 and J. Gert van Dijk
More informationTavalisse (fostamatinib disodium hexahydrate) NEW PRODUCT SLIDESHOW
Tavalisse (fostamatinib disodium hexahydrate) NEW PRODUCT SLIDESHOW Introduction Brand name: Tavalisse Generic name: Fostamatinib disodium hexahydrate Pharmacological class: Tyrosine kinase inhibitor Strength
More informationSyncope By Remus Popa
Syncope By Remus Popa A 66 years old male is brought to the ED from a restaurant where he fainted while dining out with his family. He complained of nausea and stood up to go to the restroom but immediately
More informationFaculty Disclosure. Sanjay P. Singh, MD, FAAN. Dr. Singh has listed an affiliation with: Consultant Sun Pharma Speaker s Bureau Lundbeck, Sunovion
Faculty Disclosure Sanjay P. Singh, MD, FAAN Dr. Singh has listed an affiliation with: Consultant Sun Pharma Speaker s Bureau Lundbeck, Sunovion however, no conflict of interest exists for this conference.
More informationSyncope: The Pediatric Patient
Syncope: The Pediatric Patient Lindsey Malloy-Walton, DO, MPH, FAAP Division of Pediatric Cardiology Children s Mercy Hospital 2401 Gillham Road Kansas City, MO 64108 Phone (office): 816-234-3255 Email:
More informationIvabradine in treatment of sinus tachycardia mediated vasovagal syncope
Europace Advance Access published September 26, 2013 Europace doi:10.1093/europace/eut226 CLINICAL RESEARCH Ivabradine in treatment of sinus tachycardia mediated vasovagal syncope Richard Sutton 1,2 *,
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationEffectiveness of Fludrocortisone and Salt in Preventing Syncope Recurrence in Children A Double-Blind, Placebo-Controlled, Randomized Trial
Journal of the American College of Cardiology Vol. 45, No. 4, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.11.033
More informationHypotensive susceptibility and antihypertensive drugs Diana Solari Santa Margherita Ligure, 7 aprile 2016
Hypotensive susceptibility and antihypertensive drugs Diana Solari Santa Margherita Ligure, 7 aprile 2016 Arrhythmologic Center, Department of Cardiology, Lavagna SYNCOPE AND ANTIHYPERTENSIVE DRUGS Many
More informationShared Care Guideline
Shared Care Guideline Midodrine for Orthostatic hypotension and neurocardiogenic syncope Executive Summary Update of Guideline following licencing of drug. The responsibility for initiating midodrine will
More informationPoTS; the King s approach. Dr. Nick Gall King s College Hospital London, UK
PoTS; the King s approach 2017 Dr. Nick Gall King s College Hospital London, UK The King s PoTS experience Appointed in 2004 Cardiac electrophysiologist Occasional patients with PoTS / IST Anticoagulant
More informationFor the Faint of Heart
For the Faint of Heart Developing a Simple Consistent Approach to Diagnosis of Syncope/PoTS R. Austin Raunikar, MD, FAAP, FACC Clinical Associate Professor, USCSOM Greenville Pediatric Cardiology, GHS
More informationORIGINAL ARTICLE. Edgardo Kaplinsky, Francesc Planas Comes, Ludmila San Vicente Urondo, Francesc Planas Ayma
ORIGINAL ARTICLE Cardiology Journal 2010, Vol. 17, No. 2, pp. 166 171 Copyright 2010 Via Medica ISSN 1897 5593 Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: A three month-long
More informationdroxidopa (Northera )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTreatment of Dysautonomia in the Joint Hypermobility Syndrome
Treatment of Dysautonomia in the Joint Hypermobility Syndrome Jaime F. Bravo, MD San Juan de Dios Hospital, Rheumatology Dept. University of Chile Medical School. Santiago, Chile Causes of Dysautonomia
More informationDeath after Syncope: Can we predict it? Daniel Zamarripa, MD Senior Medical Director December 2013
Death after Syncope: Can we predict it? Daniel Zamarripa, MD Senior Medical Director December 2013 Death after Syncope: Can we predict it? Those who suffer from frequent and severe fainting often die suddenly
More informationNeurogenic orthostatic hypotension: the very basics
Clin Auton Res (2017) 27:39 43 DOI 10.1007/s10286-017-0437-3 EDITORIAL Neurogenic orthostatic hypotension: the very basics Horacio Kaufmann 1 Jose-Alberto Palma 1 Received: 7 June 2017 / Accepted: 8 June
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationthe study to patients evaluated clinically by 2 of the authors (P.S., P.A.L.). Symptoms of orthostatic intolerance, aggravating factors, antecedent il
ORIGINAL ARTICLE POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME Postural Orthostatic Tachycardia Syndrome: The Mayo Clinic Experience MARK J. THIEBEN, MD; PAOLA SANDRONI, MD, PHD; DAVID M. SLETTEN; LISA M.
More informationApplying Syncope Guidelines to Clinical Practice
Applying Syncope Guidelines to Clinical Practice ACC Rockies February 27, 2018 Roopinder K Sandhu Associate Professor of Medicine U of A Director of Edmonton Cardiac Arrhythmia Trials Research Group Visiting
More informationDesmopressin Version 2.0. Public summary of the Risk Management Plan
Desmopressin 16.12.2015 Version 2.0 Public summary of the Risk Management Plan VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bedwetting Bedwetting (also called primary nocturnal
More informationThe diagnosis of orthostatic intolerance (OI) and postural tachycardia syndrome (POTS) is based on a symptomatic, excessive
Postural Tachycardia in Children and Adolescents: What is Abnormal? Wolfgang Singer, MD 1, David M. Sletten, BA 1, Tonette L. Opfer-Gehrking, LPN 1, Chad K. Brands, MD 2, Philip R. Fischer, MD 2, and Phillip
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationPOSTURAL TACHYCARDIA SYNDROME (PoTS)
Information Booklet POSTURAL TACHYCARDIA SYNDROME (PoTS) www.potsuk.org info@potsuk.org 1 CONTENTS What is PoTS? What are the symptoms of PoTS? How is PoTS diagnosed? What causes PoTS? What can I do to
More informationSyncope (From a Cardiologist s Perspective) Patrick Henderson, DO 118 th OOA Annual Convention Internal Medicine Specialty Track April 28 th, 2018
Syncope (From a Cardiologist s Perspective) Patrick Henderson, DO 118 th OOA Annual Convention Internal Medicine Specialty Track April 28 th, 2018 No financial disclosures to report Goals Formally define
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationSYNCOPE. DEFINITION Syncope is defined as sudden and transient loss of consciousness which is secondary to period of cerebral ischemia CAUSES
SYNCOPE INTRODUCTION Syncope is a symptom not a disease Syncope is the abrupt and transient loss of consciousness associated with absence of postural tone, followed by complete and usually rapid spontaneous
More informationPostural Orthostatic Tachycardia Syndrome (POTS)
Mizumaki K Diagnosis and management of POTS Review Article Postural Orthostatic Tachycardia Syndrome (POTS) Koichi Mizumaki MD PhD Second Department of Internal Medicine, Graduate School of Medicine, University
More informationGut complications in autonomic dysfunction Qasim Aziz, PhD, FRCP
Gut complications in autonomic dysfunction Qasim Aziz, PhD, FRCP Centre for Neuroscience and Trauma Wingate Institute of Neurogastroenterology GI involvement in autonomic dysfunction Conditions Diabetes
More informationAugusto Morales, MD; Andreea I. Stoichita, MD; and Jessica D. Wharton, MD
Original Research Orthostatic Intolerance and Other Autonomic Symptoms in Adolescents With Headaches Augusto Morales, MD; Andreea I. Stoichita, MD; and Jessica D. Wharton, MD From the Department of Pediatrics,
More informationNorthera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension. September 2010
Northera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension September 2010 1 2004-2010 Chelsea Therapeutics, Inc. This presentation is being provided for
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July-August
BRAND NAME Noctiva GENERIC NAME Desmopressin acetate nasal spray MANUFACTURER Serenity Pharmaceuticals DATE OF APPROVAL March 3, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review
More informationLONG-TERM FOLLOW-UP OF DDDR CLOSED-LOOP PACING FOR RECURRENT VASO-VAGAL SYNCOPE
LONG-TERM FOLLOW-UP OF DDDR CLOSED-LOOP PACING FOR RECURRENT VASO-VAGAL SYNCOPE M. Bortnik, G. Dell'era, E. Occhetta, L. Plebani, P. Marino University of Eastern Piedmont, Department of Cardiology, Novara,
More informationHypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to
Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to 90 mmhg. These pressures are called Normal blood pressure
More informationManagement of syncope in 2014 Role of tilt test
Gdansk BEATA Symposium October 10-11, 2014 Management of syncope in 2014 Role of tilt test Antonio Raviele, MD, FESC, FHRS ALFA Alliance to Fight Atrial fibrillation, Mestre Venice, Italy Protocols /
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationMy Patient Needs a Stress Test
My Patient Needs a Stress Test Amy S. Burhanna,, MD, FACC Coastal Cardiology Cape May Court House, New Jersey Absolute and relative contraindications to exercise testing Absolute Acute myocardial infarction
More informationAfter i.v injection 45% of the amount of desmopressin is found in the urine within 24 hours.
MINIRIN Tablets 0.1 and 0.2 mg Declaration Tablets 0.1 mg. Each tablet contains desmopressin acetate 0.1 mg and excipients q.s Tablets 0.2 mg. Each tablet contains desmopressin acetate 0.2 mg and excipients
More informationDepartment of Paediatrics Clinical Guideline. Syncope Guideline
Department of Paediatrics Clinical Guideline Syncope Guideline Definition Transient, self-limited loss of consciousness (TLOC), usually leading to falling. Onset is relatively rapid. Recovery is spontaneous,
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationPOTS. Putting the Puzzle Pieces Together. Artur Fedorowski MD, Assoc.Prof. FESC Skåne University Hospital in Malmö and Lund University Sweden
POTS Putting the Puzzle Pieces Together Artur Fedorowski MD, Assoc.Prof. FESC Skåne University Hospital in Malmö and Lund University Sweden 1993 These patients were usually women who experienced an acute
More informationSyncope Guidelines Update. Bernard Harbieh, FHRS AUBMC-KMC Beirut-Lebanon
Syncope Guidelines Update Bernard Harbieh, FHRS AUBMC-KMC Beirut-Lebanon New Syncope Guidelines Increase the volume of information on diagnosis and management Incorporation of emergency specialists, neurologists,
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationSympathovagal balance analysis in idiopathic postural orthostatic tachycardia syndrome
ACTA BIOMED 2007; 78: 133-138 Mattioli 1885 C A S E R E P O R T Sympathovagal balance analysis in idiopathic postural orthostatic tachycardia syndrome Vincenzo Russo, Ilaria De Crescenzo, Ernesto Ammendola,
More informationDDAVP Tablets (desmopressin acetate) Rx only
DDAVP Tablets (desmopressin acetate) Rx only DESCRIPTION DDAVP Tablets (desmopressin acetate) are a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone
More informationChronic Fatigue Syndrome: What is the role of diet and nutrition? Sue Luscombe RD Specialist CFS Dietitian
Chronic Fatigue Syndrome: What is the role of diet and nutrition? Sue Luscombe RD Specialist CFS Dietitian My Story What is Chronic Fatigue Syndrome? Also known as CFS M.E. - Myalgic Encephalomyelitis
More informationNOCTIVA (desmopressin acetate) nasal spray
NOCTIVA (desmopressin acetate) nasal spray Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationSevere Hypertension. Pre-referral considerations: 1. BP of arm and Leg 2. Ambulatory BP 3. Renal causes
Severe Hypertension *Prior to making a referral, call office or Doc Halo, to speak with a Cardiologist or APP to discuss patient and possible treatment options. Please only contact the patient's cardiologist.
More informationNocturnal polyuria has been linked to abnormalities of the daily rhythm of (circadian rhythmic) release of naturally occurring antidiuretic hormone.
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bedwetting Bedwetting (also called primary nocturnal enuresis) is probably the most common developmental problem in children,
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationInternational Journal of Case Studies in Clinical Research
Case Report Postural Tachycardia Syndrome International Journal of Case Studies in Clinical Research Open Access 1 Marieke J. Kuiper, 2 Salah A.M. Said, 3 Ali Agool 1 Medical student, University Medical
More information6/13/2017 PROFESSOR CHRISTOPHER J MATHIAS. Non-motor features in PD AUTONOMIC NERVOUS SYSTEM. Motor. Non-Motor CLINICAL AUTONOMIC MANIFESTATIONS
PRFESSR CRISTPER J MATIAS Autonomic & Neurovascular Medicine Centre and The Joint ypermobility Unit, ospital of St John & St Elizabeth, St Johns Wood, London Autonomic Dysfunction in Parkinsons Disease:
More informationAF Diagnosis. Incorporated into over 75 health checks and Public Health Checks
AF Diagnosis Incpated into over 75 health checks and Public Health Checks Pulse Feel the pulse in all >65yrs If irregular do a 12 Lead ECG with Rhythm strip Check Thyroid and FBC and heart rate Refer to
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationAtrial fibrillation: Who should be referred for ablation therapy for atrial fibrillation?. September 12 th, 2015
Atrial fibrillation: Who should be referred for ablation therapy for atrial fibrillation?. September 12 th, 2015 MMMMMMM MMMMMMM MMMMMMM Sohail Hassan MD FACC, FHRS Director, Cardiac Electrophysiology
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationExercise hemodynamics in Parkinson s Disease and autonomic dysfunction
Exercise hemodynamics in Parkinson s Disease and autonomic dysfunction David A. Low 1,2,3*, Ekawat Vichayanrat 2,3, Valeria Iodice 2,3 and Christopher J. Mathias 2,3 1 Research Institute of Sport and Exercise
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More information